Tofisopam is a new agent marketed in Europe as a minor tranquilizer. The
authors conducted a 4-week double-blind trial of this drug compared with
placebo in 57 outpatients with anxiety and depression. They found that
according to physician ratings and patient self-ratings tofisopam was an
effective anxiolytic agent for subjects with anxiety and depression.
Twenty-one percent of the patients receiving tofisopam and 10% of those
receiving placebo reported side effects. The drug was especially effective
in the treatment of somatic difficulties.